ReviewJournal of pharmaceutical sciences2008
Nanovehicular intracellular delivery systems.
Review in Journal of pharmaceutical sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics.Current issues in molecular biology · 2026Review
- Repurposing gabapentin and pregabalin to improve the anticancer efficacy of 5-fluorouracil through development of a dual-drug-loaded nanoformulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Biopolymer-Nanoparticle Interactions in 3D-Printing for Biomedical Applications: Advantages, Limitations and Future Perspectives.Polymers · 2026Review
- Nanoparticles: An Emerging Hope in Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026Review
- Advances in PLGA-based polymeric nanocarriers for colorectal cancer therapy: overcoming chemoresistance through controlled delivery strategies.Molecular cancer · 2025Review
- From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications.Pharmaceutics · 2025Review
- Herbal based nanoparticles as a possible and potential treatment of cancer: a review.Exploration of targeted anti-tumor therapy · 2025Review
- Anticancer Effects of MAPK6 siRNA-Loaded PLGA Nanoparticles in the Treatment of Breast Cancer.Journal of cellular and molecular medicine · 2025Article
- Plant-derived Exosomes: Pioneering Breakthroughs in Therapeutics, Targeted Drug Delivery, and Regenerative Medicine.Pharmaceutical nanotechnology · 2025Review
- Unraveling the Pivotal Role of Nanovesicle Drug Delivery Systems in Colorectal Cancer: A New Paradigm in Therapeutics.Current pharmaceutical design · 2025Review
- Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment.RSC advances · 2024Review
- Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment".International journal of molecular sciences · 2024Review
- Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024Review
- Autonomous Nanorobots as Miniaturized Surgeons for Intracellular Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis.Chemical science · 2024Review
- Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics.Beilstein journal of nanotechnology · 2024Article
- Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.Stem cell reviews and reports · 2023Review
- Advancement in Biopolymer Assisted Cancer Theranostics.ACS applied bio materials · 2023Review
- Review
- Remote Activation of Enzyme Nanohybrids for Cancer Prodrug Therapy Controlled by Magnetic Heating.ACS nano · 2023Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This article provides an overview of principles and barriers relevant to intracellular drug and gene transport, accumulation and retention (collectively called as drug delivery) by means of nanovehicles (NV). The aim is to deliver a cargo to a particular intracellular site, if possible, to exert a local action. Some of the principles discussed in this article apply to noncolloidal drugs that are not permeable to the plasma membrane or to the blood-brain barrier. NV are defined as a wide range of nanosized particles leading to colloidal objects which are capable of entering cells and tissues and delivering a cargo intracelullarly. Different localization and targeting means are discussed. Limited discussion on pharmacokinetics and pharmacodynamics is also presented. NVs are contrasted to micro-delivery and current nanotechnologies which are already in commercial use. Newer developments in NV technologies are outlined and future applications are stressed. We also briefly review the existing modeling tools and approaches to quantitatively describe the behavior of targeted NV within the vascular and tumor compartments, an area of particular importance. While we list "elementary" phenomena related to different level of complexity of delivery to cancer, we also stress importance of multi-scale modeling and bottom-up systems biology approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.